Organization
Foundation Medicine Inc, Morrisville, NC
7 abstracts
Abstract
Tumor mutational burden (TMB) measurement from an FDA-approved assay and real-world overall survival (rwOS) on single-agent immune checkpoint inhibitors (ICI) in over 8,000 patients across 24 cancer types.Org: Flatiron Health, San Francisco, CA, Foundation Medicine, Inc., Cambridge, MA, Foundation Medicine Inc, Morrisville, NC, Flatiron Health, New York, NY, Flatiron Health, Dallas, TX,
Abstract
Preliminary results of the Lung Cancer Mutation Consortium LCMC4 evaluation of actionable drivers in early stage lung cancer (LEADER) screening trial.Org: Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College University, Dana-Farber Cancer Institute, Ronald Reagan UCLA Medical Center, University of Michigan,
Abstract
HRD signature and HRD genomic landscape of tumors from 896 patients with early-stage breast cancer (BC).Org: Yale School of Medicine, Foundation Medicine, Inc., Cambridge, MA, Foundation Medicine Inc, Morrisville, NC, Yale Cancer Center, Yale School of Medicine, New Haven, CT,
Abstract
Penile squamous cell carcinoma (PSCC) with elevated tumor mutational burden (TMB): A genomic landscape study.Org: H. Lee Moffitt Cancer Center and Research Institute, University of Washington; Fred Hutchinson Cancer Center, The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Vita-Salute San Raffaele University, Foundation Medicine, Inc., Cambridge, MA,
Abstract
SPARK, studying pathways of resistance in KRAS-driven cancers: A remote plasma ctDNA participation study to identify mechanisms of resistance to KRAS inhibitors.Org: Dana-Farber Cancer Institute, Lowe Center for Thoracic Oncology, Kras Kickers, GO2 Foundation for Lung Cancer, Addario Lung Cancer Medical Institute,
Abstract
Tumor mutational burden (TMB) in real-world patients with pancreatic ductal adenocarcinoma (PDAC): Differences in genomic alterations (GA) and predictive value for immune checkpoint inhibitor (ICI) effectiveness.Org: Foundation Medicine, Inc., Cambridge, MA, Mayo Clinic, Foundation Medicine Inc, Morrisville, NC,
Abstract
CDH1-mutated clinically advanced urothelial bladder cancer (UBC): A genomic landscape and real-world clinical outcome study (RWCOS).Org: H. Lee Moffitt Cancer Center and Research Institute, Vita-Salute San Raffaele University, Saint Louis University Hospital, University of Washington; Fred Hutchinson Cancer Center, SUNY Upstate Medical University,